15 Most Undervalued Large Cap Stocks to Invest In Now

Page 9 of 14

6. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 84

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a relatively quiet earnings call, shifting investor focus toward the timing and framing of VESPER-3 obesity data.

Additionally, Cantor Fitzgerald suggested that incremental updates regarding the Lyme disease vaccine, mevro for prostate cancer, and sigvotatug vedotin for non-small cell lung cancer will likely be more influential than the Q4 2025 results.

In other news, on January 10, Pfizer announced positive results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab and FOLFIRI for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. The study showed a statistically significant and clinically meaningful confirmed objective response rate of 64.4% compared to 39.2% for patients receiving the standard-of-care FOLFIRI regimen. These findings suggest that the BRAFTOVI combination provides a durable response and potential flexibility in chemotherapy backbones for this aggressive cancer.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. The company offers medicines and vaccines in various therapeutic areas.

Page 9 of 14